Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)



Status:Recruiting
Conditions:Lymphoma
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/5/2016
Start Date:June 2015
End Date:April 2018
Contact:Toll Free Number
Phone:1-888-577-8839

Use our guide to learn which trials are right for you!

A Phase II Clinical Trial of MK-3475 (Pembrolizumab) in Subjects With Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL)

This is a study of pembrolizumab for participants with relapsed/refractory classical Hodgkin
Lymphoma (RRcHL) who 1) have failed to achieve a response or progressed after autologous
stem cell transplant (auto-SCT) and have relapsed after treatment with or failed to respond
to brentuximab vedotin (BV) post auto-SCT or 2) were unable to achieve a Complete Response
(CR) or Partial Response (PR) to salvage chemotherapy and did not receive auto-SCT, but have
relapsed after treatment with or failed to respond to BV or 3) have failed to achieve a
response to or progressed after auto-SCT and have not received BV post auto-SCT.

The primary study hypothesis is that treatment with single agent pembrolizumab will result
in a clinically meaningful overall response rate.


Inclusion criteria:

- Relapsed or refractory de novo classical Hodgkin lymphoma

- Participant may have failed to achieve a response to, progressed after, or be
ineligible for autologous stem cell transplant (auto-SCT)

- Participant may have failed to achieve a response or progressed after treatment with
brentuximab vedotin or may be brentuximab vedotin naïve

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

- Measurable disease

- Adequate organ function

Exclusion criteria:

- Diagnosis of immunosuppression or receiving systemic steroid therapy or any other
form of immunosuppressive therapy within 7 days prior to the first dose of study
medication

- Prior monoclonal antibody within 4 weeks prior to study Day 1 or chemotherapy,
targeted small molecular therapy, or radiation therapy within 2 weeks prior to study
Day 1

- Prior allogeneic hematopoietic stem cell transplantation

- Known clinically active central nervous system involvement

- Known additional malignancy that is progressing or requires active treatment

- Has a known history of Human Immunodeficiency Virus (HIV)

- Has known active Hepatitis B (HBV) or Hepatitis C (HCV)

- Active autoimmune disease requiring systemic treatment in past 2 years

- Evidence of active, non-infectious pneumonitis
We found this trial at
17
sites
5
mi
from 91732
Duarte, CA
Click here to add this to my saved trials
2437
mi
from 91732
Albany, NY
Click here to add this to my saved trials
1213
mi
from 91732
Austin, TX
Click here to add this to my saved trials
1784
mi
from 91732
Birmingham, AL
Click here to add this to my saved trials
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
1729
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
Colorado Springs, Colorado 80910
804
mi
from 91732
Colorado Springs, CO
Click here to add this to my saved trials
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
2435
mi
from 91732
New York, NY
Click here to add this to my saved trials
1722
mi
from 91732
Niles, IL
Click here to add this to my saved trials
827
mi
from 91732
Portland, OR
Click here to add this to my saved trials
1524
mi
from 91732
Rochester, MN
Click here to add this to my saved trials
1188
mi
from 91732
San Antonio, TX
Click here to add this to my saved trials
964
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
683
mi
from 91732
Springfield, OR
Click here to add this to my saved trials
328
mi
from 91732
Stanford, CA
Click here to add this to my saved trials